ArticleCancer communications (London, England)2025
Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics.
Abstract read
In one paragraph
Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epithelioid Sarcoma: A Review and Update.Cancers · 2026Review
- Circulating Tumor Cells in Soft Tissue Sarcoma: Current Evidence and Clinical Implications.Cancers · 2026Review
- Dissecting the role of KLF5: from tumor progression to immune interactions with emphasis on glioma and bladder cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Carine NgoEuropean Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France.ORCID https://orcid.org/0000-0002-8172-5876
Léo Colmet-DaageEuropean Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France.
Julien VibertEuropean Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France.
Clémence HénonDepartment of Therapeutic Innovation and Early Clinical Trials, Institut Gustave Roussy, Villejuif, France.
Daniel PissalouxNational Institute of Health and Medical Research 1052, French National Centre for Scientific Research 5286, Cancer Research Center of Lyon, Lyon, France.
Alexander ValentDepartment of Pathology and Laboratory Medicine, Institut Gustave Roussy, Villejuif, France.
Jia Xiang JinDivision of Translational Pediatric Sarcoma Research (B410), German Cancer Research Center, German Cancer Consortium, Heidelberg, Germany.
Riwan BrilletEuropean Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France.
Julien Masliah-PlanchonSomatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medicine, Institut Curie Hospital, Paris, France.
Gaëlle PierronSomatic Genetic Unit, Department of Pathology and Diagnostic and Theranostic Medicine, Institut Curie Hospital, Paris, France.
Ludovic LacroixDepartment of Pathology and Laboratory Medicine, Institut Gustave Roussy, Villejuif, France.
Etienne RouleauDepartment of Pathology and Laboratory Medicine, Institut Gustave Roussy, Villejuif, France.
Cyril Roussel-SimoninDepartment of Therapeutic Innovation and Early Clinical Trials, Institut Gustave Roussy, Villejuif, France.
Lilian LecorgneEuropean Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France.
Clémence AstierEuropean Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France.
Marlène GarridoEuropean Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France.
Rastislav BahledaDepartment of Therapeutic Innovation and Early Clinical Trials, Institut Gustave Roussy, Villejuif, France.
Benjamin VerretDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Axel Le CesneDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Charles HonoreSurgery Department, Institut Gustave Roussy, Villejuif, France.
Matthieu FaronSurgery Department, Institut Gustave Roussy, Villejuif, France.
Wolf Herman FridmanCentre de Recherche des Cordeliers, Sorbonne University, National Institute of Health and Medical Research, Paris University, The French League Against Cancer, Paris, France.
Catherine Sautès-FridmanCentre de Recherche des Cordeliers, Sorbonne University, National Institute of Health and Medical Research, Paris University, The French League Against Cancer, Paris, France.
Jean-Michel CoindreDepartment of Pathology, Institut Bergonié, Bordeaux, France.
Jean-Yves ScoazecDepartment of Pathology and Laboratory Medicine, Institut Gustave Roussy, Villejuif, France.
Joshua J WaterfallNational Institute of Health and Medical Research U830, Integrative Functional Genomics of Cancer Lab, Paris Sciences & Lettres Research University, Institut Curie Research Center, Paris, France.
Franck BourdeautParis-Cité University & Expert Center in Childhood and Adolescent Oncology Center, National Institute of Health and Medical Research U830, Institut Curie Research Center, Paris, France.
Thomas G P GrünewaldDivision of Translational Pediatric Sarcoma Research (B410), German Cancer Research Center, German Cancer Consortium, Heidelberg, Germany.
Jean-Yves BlayNational Institute of Health and Medical Research 1052, French National Centre for Scientific Research 5286, Cancer Research Center of Lyon, Lyon, France.
Franck TirodeNational Institute of Health and Medical Research 1052, French National Centre for Scientific Research 5286, Cancer Research Center of Lyon, Lyon, France.
Sophie Postel-VinayEuropean Research Council Starting Grant, Targeting Genetic and Epigenetic Vulnerabilities in Solid Tumors and Sarcoma, National Institute of Health and Medical Research U981, Institut Gustave Roussy, Paris Saclay University, Villejuif, France.
Funding
Cancéropôle Ile de France 2017-1-EMERG-72Cancéropôle Ile de France 2020-1-EMRG-28-IGR-1Fondation ARC pour la Recherche sur le Cancer PGA1-RF20190208576Fondation Gustave RoussyInstitut National Du Cancer INCa-DGOS-Inserm_12551 SIRIC2Institut National Du Cancer INCa-DGOS-Inserm-ITMO Cancer_18002 SIRIC EpiCURELigue Contre le Cancer(PGA1-RF20190208576), European Research Council 101077864
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.